NCT00450775已完成4 期
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- efficacy
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Female or male patients at least 18 years of age
- •Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
- •Able and willing to provide informed consent and likely to complete all study visits
- •All Fitzpatrick skin types will be evaluated
排除标准
- •Known contraindications to Dermatix or any of its components
- •Age of scar is > 4 months
- •Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)
研究组 & 干预措施
1
Other
干预措施: Dermatix Q (Drug)
结局指标
主要结局
efficacy
时间窗: 1 yr
次要结局
- patient acceptance(1 yr)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Gammagard Liquid and rHuPH20 in PIDPrimary Immunodeficiency Diseases (PID)NCT00814320Baxalta now part of Shire89
已完成
不适用
A Study of a Whole-Body Balm on Newborn BabiesHealthyNCT05786209Johnson & Johnson Consumer Inc. (J&JCI)28
已完成
不适用
Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic DermatitisAtopic DermatitisNCT05531188Cosmetique Active International68
已完成
不适用
Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic AcidSkin FoldsWrinkleNCT05450380Mesoestetic Pharma Group S.L.50
招募中
不适用
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)DermatomyositisNCT02945345University of Pennsylvania300